Please login to the form below
Merck and Co.
This page shows the latest Merck and Co. news and features for those working in and with pharma, biotech and healthcare.
MSD and Eisai’s combination therapy recommended by NICE for advanced endometrial cancer
MSD’s – known as Merck &Co in the US and Canada – Keytruda (pembrolizumab) in combination with Eisai’s Lenvima (lenvatinib) has been recommended by the National Institute for Health and Care ... We are proud to have worked alongside Eisai, NICE
Latest news
-
Incyte and Biotheryx collaborate to develop protein degraders for oncology targets
Merck &Co – known as MSD outside the US and Canada – and Proxygen also announced a partnership to identify molecular glue degraders on the same day. ... Under this collaboration, Proxygen will receive an upfront payment from Merck in exchange for
-
MSD’s Keytruda to be made available in England for advanced cervical cancer patients
MSD’s – known as Merck &Co in the US and Canada – Keytruda (pembrolizumab) in combination with chemotherapy will be made immediately available to hundreds of advanced cervical cancer patients through ... While cervical cancer can be curable when
-
AstraZeneca’s mild combination asthma reliever approved in UK
Asthma is a chronic, variable, inflammatory disease characterised by asthma attacks and symptoms including breathlessness and wheezing. ... The authorisation comes just days after AZ and MSD’s – known as Merck &Co in the US and Canada – Lynparza
-
AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
AstraZeneca and MSD's – known as Merck &Co in the US and Canada – Lynparza (olaparib) has been approved in the UK as part of a combination therapy for certain prostate cancer ... a range of indications for ovarian, breast, fallopian tube, peritoneal
-
AstraZeneca and MSD report final overall survival results from prostate cancer study
AstraZeneca and MSD – known as Merck &Co in the US and Canada – have reported final overall survival results from a phase 3 trial of a Lynparza (olaparib) combination in metastatic ... The drug also holds a number of approvals for a range of
More from news
Approximately 44 fully matching, plus 530 partially matching documents found.
Latest Intelligence
-
Envisioning a healthier every day, for every woman
By Sandy Lindsey. It’s little over a year since the bell first rang on the New York Stock Exchange announcing the arrival of Organon &Co, a spin-off from MSD ... known as Merck &Co in the US and Canada) with a mission to create improved health outcomes
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
Similarly, Novartis formed the investment firm Novartis Venture Funds and Merck &Co. ... created the Merck Research Venture Fund. Nowadays, having a venture arm to proactively research for outside R&D sourcing is common for most mid- to large- sized
-
AI: the smart money is on the smart thinking
Bayer and Merck &Co provide a perfect example of this. They have developed an AI software system to support clinical decision-making of chronic thromboembolic pulmonary hypertension (CTEPH) – a rare form ... Bayer and Merck &Co hope that radiologists
-
Can protein degraders unlock ‘undruggable’ drug targets?
like Novartis, Amgen, Pfizer and Merck &Co/MSD. ... which adds to previous collaborations with Roche’s Genentech subsidiary, Pfizer, and also Merck &Co/MSD that committed $434m to the company shortly after it launched in 2013.
-
Vertex: a vision of treating all CF patients worldwide draws closer
Ex-Merck &Co. scientist Joshua Boger did want the company to pioneer rationale drug discovery and development, however, and after. ... a loss in almost all of its 20+ years, and has cumulative net losses of around $3bn.
More from intelligence
Approximately 0 fully matching, plus 45 partially matching documents found.
Latest appointments
-
Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
Arnhofer joins the agency with two decades of experience in the biopharma industry, having held a variety of senior positions at Merck &Co, Bayer AG and BioNTech SE. ... Storyteq marketing collaboration and creative automation platform, in addition to
-
Merck & Co appoints Frank Clyburn as president, human health
Merck &Co – known as MSD outside the US and Canada – has appointed Frank Clyburn (pictured above) as president, human health. ... Clyburn joined Merck &Co in 2008 and during his time with the company, he has had responsibility for various global
-
Weekly industry appointments
Laboratories and Merck &Co. ... to help take Abcam to the next stage in its development and growth.”.
-
Nabriva Therapeutics appoints chief medical officer
Schranz. Dr Schranz joins Nabriva from Irish biopharma Shire, with nearly two decades of experience in clinical development and medical affairs. ... Her career has seen her hold positions at Shire, ViroPharma, Pfizer, GlaxoSmithKline and Merck &Co.
-
Hansa Medical poaches Vifor Pharma’s CEO
Tulstrup was most recently CEO of Swiss pharmaceutical group Vifor Pharma and prior to this he served as senior vice president, global franchise head at Shire. ... Additionally, Tulstrup has served as CEO of Santaris Pharma, now part of Roche, and in
More from appointments
Approximately 4 fully matching, plus 35 partially matching documents found.
Latest from PMHub
-
Practical Patient Centricity
Merck &Co, Sanofi and UCB have identified the competitive advantage that patient centricity brings and are leading the way in its practical implementation. ... Patient centricity is the next market access – and will take 10 years to embed”.
-
Digital Marketing is no Substitute for Sound Strategic Marketing
With a stronger market access focus, companies can create and implement stronger marketing strategies. ... With no prior blueprint on how to ‘go digital’ in their marketing, early pioneer companies such as Merck &Co.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Wilmington Healthcare
A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...
Latest intelligence
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- ...
- Working together to achieve better patient pathways
- Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
- Design-thinking. Iterating for continuous improvement.
- How design can lead improvement within Pharma...
